

Summary: Cost-effectiveness of end-game strategies against sleeping sickness across the Democratic Republic of Congo

Marina Antillon^{1,2}, Ching-I Huang^{3,4,†}, Samuel A. Sutherland^{3,5,†}, Ronald E. Crump^{3,4,†}, Paul E. Brown^{3,4}, Paul R. Bessell⁶, Emily H. Crowley^{3,4}, Rian Snijders^{1,2,7}, Andrew Hope⁸, Iñaki Tirados⁸, Sophie Dunkley⁸, Paul Verlé⁷, Junior Lebuki⁹, Chancy Shampa⁹, Erick Mwamba Miaka⁹, Fabrizio Tediosi^{1,2}, Kat S. Rock^{3,4}

1. Swiss Tropical and Public Health Institute, Allschwil, Switzerland
2. University of Basel, Basel, Switzerland
3. Zeeman Institute, University of Warwick, Coventry, UK
4. Mathematics Institute, University of Warwick, Coventry, UK
5. Warwick Medical School, University of Warwick, Coventry, UK
6. Independent consultant, Edinburgh, UK
7. Institute of Tropical Medicine, Antwerp, Belgium
8. Liverpool School of Tropical Medicine, Liverpool, UK
9. Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, Democratic Republic of Congo

† These authors contributed equally to this work.

Background: *Gambiense* human African trypanosomiasis (gHAT) is marked for elimination of transmission (EoT) by 2030. We examined the cost-effectiveness (CE) of EoT in the Democratic Republic of Congo, the country with the highest burden.

Methods: In 165 health zones (HZs), we modelled the transmission dynamics, health outcomes, and economic costs of six strategies during 2026–40, including cessation activities once reported cases reach zero. Uncertainty in CE was assessed within the net monetary framework, presenting optimal strategies across willingness-to-pay (WTP) values, in costs per disability-adjusted life-year averted. We assessed the optimal strategy for CE and EoT in each health zone separately, but present results by health zone, by coordination, and for the whole country.

Results: Status quo strategies, CE strategies (WTP=\$500), and strategies with a high probability of EoT by 2030 are predicted to yield EoT by 2030 in 118 HZs, 123 HZs, and 134 HZs respectively, at a cost by 2040 of \$67.8M [95% PI: \$36.7M–113M], \$93.3M [95% PI: \$51.6M–153M], \$185M [95% PI: \$111M–309M]. A more lenient timeline of EoT by 2040 would lead to EoT in 152 HZs at a cost of \$158M [95% PI: \$91.6–265M], leaving 13 HZs shy of the goal. Costs would have to be front-loaded; in 2026, while status quo strategies would cost \$8.75M [95% PI: \$7.01M–11.2M], elimination strategies would cost \$27.0 [95% PI: \$21.0M–35.2M]. Investing in EoT by 2030 is predicted to reduce 68% of gHAT deaths from 7979 [95% PI: 770–27,868] with status quo strategies to 2576 [95% PI: 255–9133].

Conclusions: Current tools could make considerable progress to maximise the probability of EoT by 2030, but novel tools could help in select health zones are facing a low probability of EoT even with more ambitious strategies.

E1 Introduction

This study focuses on the health economic impact of implementing six plausible gHAT control and elimination strategies for the whole of the DRC at the health zone level and under a variety of funding and elimination targets. This is an expansion of previous work described above (see [1]) that focused on five low- to high-risk health zones but scaled up to 165 health zones across the DRC. Model fits and projections are also refined from previous work through the use of an extra four years of gHAT case and screening data (see [2, 3]). Using a modelling framework, we examined the interplay of epidemiological, economic and temporal factors in effective decision-making around gHAT strategies for EoT. The objective of this piece is to estimate future resource needs including the resource implications of pursuing gHAT EoT by 2030 and which of the strategies under consideration has the highest probability of being cost-effective in these different settings.

E2 Methods

E2.1 Data

Historical case data was acquired from the WHO HAT Atlas project, which also includes records of the number of people tested in active screening activities [4]. For cost purposes, populations screened during passive screening were deduced from two data sources: the historical records of clinics capable of screening with serological tests (RDT or CATT) [5], and records acquired from the PNLTHA for the years 2019–2020. Cost data was acquired from the literature and conversations with program staff ([6, 7], among others).

E2.2 Transmission model fit to data

For this study, we used the previously published Warwick gHAT model [2] consisting of a mechanistic modelling framework to explicitly simulate transmission between humans via tsetse vectors (see Supplementary Figure E1). The model parameterisation has recently been updated by fitting to WHO HAT Atlas data from 2000–2020 for health zones in the DRC that had sufficient data (at least 10 data points, where any year with active screening and any year with non-zero passive case detection count as individual data points). Furthermore, the modelling framework has been updated to capture stochastic dynamics and is better able to estimate the time until EoT. Moreover, we fit also the data to a model variant with animal reservoirs which considers the possibility that animals can acquire and transmit infections to and from tsetse (as per [8] but with an extra four years of data). Our final projections will consist of an “ensemble” of samples of projections from both models – with and without animal reservoirs. The proportion of samples from both models will be determined by the statistical support of each model based on the data. The health zones included in the analysis are described in Table E2.

E2.3 Epidemiological projections

Projections under six plausible gHAT control and intervention strategies were simulated from 2026–2055 and are displayed in Figure E2; two health zones in the Bas Uélé region – Ango and Doruma – have alternative strategies due to the special situations in these health zones. Each activity is further explained in Table E1. The *Targeted VC* strategy uses an adapted algorithm based on that previously used by LSTM to identify large rivers with recent nearby high case density at which to focus Tiny Target deployment. The *Full VC* strategy, by contrast, involves an expansion of VC interventions, considering the deployment of Tiny Targets throughout all large rivers in a health zone. All strategies feature the continuation of the current PS. All strategies assume that AS will cease after 3 years of AS with zero cases in either AS or PS, followed by another AS in year 5 with no cases, an algorithm referred to as the ‘3+1 algorithm’. Reactive screening (RS) is triggered if a case is found in PS and stops using the same 3+1 algorithm. VC stops after 3 years of no cases. PS is stopped 5 years after AS and RS have ceased. PS is assumed to remain constant for the duration of our simulations, even after cessation of AS and VC and presumed EoT. Fexinidazole is simulated as being available immediately, but acoziborole is not included in this analysis.

For each case, we model the disease outcomes as depicted in Figure E3.

E2.4 Economic evaluation and investment horizon

We adopted the net-benefits framework, which expresses the probability that an intervention is optimal at a range of thresholds, known as the willingness-to-pay (WTP) thresholds. We computed net monetary benefits by taking the mean difference in costs and monetised health effects (DALYs $\times$ willingness-to-pay value). As per recent recommendations from the WHO, we refrained from selecting a specific ICER that would be considered “cost-effective”, and we aimed to make recommendations after accounting for uncertainty.

We examined health and cost impacts in the long term (2026–2040) to assess the returns on investments in both augmented disease control and elimination. Costs are presented in their undiscounted version for pragmatic reasons but for the selection of cost-effectiveness, both costs and health outcomes are discounted at a yearly rate of 3%.

A glossary of epidemiology and health economic terms is found in the Supplementary Note 1 and in Section E5 of this summary.

E3 Results

Figure E4 summarises the optimal strategy for each of the 165 health zones included in this analysis at each WTP threshold (status quo, minimum cost, WTP=\$250, and WTP=\$500) and the strategy necessary to maximise the probability of EoT by 2030 and a more lenient goal date of 2040. Modelling suggests that 119 health zones switch strategies to maximize their probability of EoT by 2030. For a more lenient goal of EoT by 2040, 94 health zones need to change strategies from their status quo strategies.

National-level results are summarised in Figure E5. With the current strategies, we expect that 118 (out of 165) health zones will reach EoT by 2030. Switching 119 health zones to EoT-maximising strategies, 16 more health zones are expected to reach the goal, for a total of 134 health zones. The low expectation of EoT even after we change to strategies with a better probability reaching the goal is because 66 health zones have a probability of EoT by 2030 < 90% even under the more effective strategy possible.

Costs and effects at different levels of investment In terms of total investments, by 2040, the status quo strategies will cost \$67.8M, the minimum cost strategies will cost \$64.5M, cost-effective strategies at WTP=\$250/DALY and WTP=\$500/DALY will cost \$81.4M and \$93.3M and EoT by 2030 will cost \$185M (Figure E6). The current costs are \$8.75M for 2026, but would have to increase to \$27.0M for to reach EoT by 2030. Delaying the goal until 2040 saves \$27.1M compared to implementing strategies aimed at EoT by 2030.

The status quo strategies will bring an expected 7979 deaths or 175K (discounted) DALYs by 2040 and minimum cost strategies would bring about 7988 deaths or 175K DALYs. However, 1405 of those deaths are expected to be in the two health zones of Bas Uélé alone (Figure E6, Figure E10). Strategies to reach EoT by 2030 would 241 fewer reported cases while averting 5402 deaths and 114K DALYs for an additional cost of \$118M when compared to the *Status Quo*.

The largest portion of the costs at any level of investment will go to screening activities (see Figure E16). Although the cost of treatment is quite small in relative terms, timely access to treatment is pivotal for strategies to remain effective.

All results are available, stratified by coordination, in Figures E7–E17 and stratified by health zone and coordination in the GUI <https://hatmepp.warwick.ac.uk/DRCCEA/v8/>.

E4 Discussion

Financial resources will have to increase for a short period to reach EoT by 2030. Expanded strategies will be necessary in some health zones, particularly in the east where uncertainty makes the analysis favour more intense strategies. In Kongo Central and in all but one health zone of Equateur Nord, current strategies appear to be on track for EoT by 2030.

Future analysis for the DRC, which is currently outside the scope of this study, will look at 1. the potential impact of strategies that use acoziborole as a single-dose treatment and 2. the premium paid for EoT above and beyond what would be considered a cost-effective use of resources compared to other health programmes using our new “net monetary and elimination benefits” framework [9].

References

1. Antillon M, Huang CI, Crump RE, Brown PE, Snijders R, Miaka EM, Keeling MJ, Rock KS, and Tediosi F. Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo. *Nature Communications* 2022 Dec; 13:1051. doi: [10.1038/s41467-022-28598-w](https://doi.org/10.1038/s41467-022-28598-w). Available from: <https://doi.org/10.1101/2020.08.25.20181982%20https://www.nature.com/articles/s41467-022-28598-w>
2. Crump RE, Huang CI, Knock ES, Spencer SEF, Brown PE, Mwamba Miaka E, Shampa C, Keeling MJ, and Rock KS. Quantifying epidemiological drivers of gambiense human African Trypanosomiasis across the Democratic Republic of Congo. *PLOS Computational Biology* 2021 Jan; 17. Ed. by Perkins A:e1008532. doi: [10.1371/journal.pcbi.1008532](https://doi.org/10.1371/journal.pcbi.1008532). Available from: <https://dx.plos.org/10.1371/journal.pcbi.1008532>
3. Huang CI, Crump RE, Brown PE, Spencer SE, Miaka EM, Shampa C, Keeling MJ, and Rock KS. Identifying regions for enhanced control of gambiense sleeping sickness in the Democratic Republic of Congo. *Nature Communications* 2022; 13:1–11. doi: [10.1038/s41467-022-29192-w](https://doi.org/10.1038/s41467-022-29192-w)
4. World Health Organization. Global Health Observatory data repository. 2020. Available from: <https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hat-tb-gambiense>
5. Checchi F, Funk S, Chandramohan D, Haydon DT, and Chappuis F. Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis. *BMC Research Notes* 2015; 8:8–10. doi: [10.1186/s13104-015-1244-3](https://doi.org/10.1186/s13104-015-1244-3)
6. Snijders R, Fukinsia A, Claeys Y, Mpanya A, Hasker E, Meheus F, Miaka E, and Boelaert M. Cost of a new method of active screening for human African trypanosomiasis in the Democratic Republic of the Congo. *PLOS Neglected Tropical Diseases* 2020 Dec; 14. Ed. by Ndung'u JM:e0008832. doi: [10.1371/journal.pntd.0008832](https://doi.org/10.1371/journal.pntd.0008832). Available from: <https://dx.plos.org/10.1371/journal.pntd.0008832>
7. Snijders R, Fukinsia A, Claeys Y, Hasker E, Mpanya A, Miaka E, Meheus F, and Boelaert M. Costs and outcomes of integrated human African trypanosomiasis surveillance system using rapid diagnostic tests, Democratic Republic of the Congo. *Emerging Infectious Diseases* 2021; 27:2144–53. doi: [10.3201/eid2708.202399](https://doi.org/10.3201/eid2708.202399)
8. Crump RE, Huang CI, Spencer SE, Brown PE, Shampa C, Miaka EM, and Rock KS. Modelling to infer the role of animals in gambiense human African trypanosomiasis transmission and elimination in the DRC. *PLoS Neglected Tropical Diseases* 2022; 16:1–23. doi: [10.1371/JOURNAL.PNTD.0010599](https://doi.org/10.1371/JOURNAL.PNTD.0010599)
9. Antillon M, Huang CI, Rock KS, and Tediosi F. Economic evaluation of disease elimination: An extension to the net-benefit framework and application to human African trypanosomiasis. *Proceedings of the National Academy of Sciences* 2021 Dec; 118:1–8. doi: [10.1073/pnas.2026797118](https://doi.org/10.1073/pnas.2026797118). Available from: <https://www.medrxiv.org/content/early/2021/05/02/2021.02.10.20181974%20https://pnas.org/doi/full/10.1073/pnas.2026797118>
10. Bertram MY, Lauer JA, Joncheere KD, Edejer T, Hutubessy R, Kieny P, Hill SR, and Bertram MY. Cost – effectiveness thresholds: pros and cons. *Bull World Health Organization* 2016; 94:925–30. doi: [10.2471/BLT.15.164418](https://doi.org/10.2471/BLT.15.164418)
11. Marseille E, Larson B, Kazi DS, Kahn JG, and Rosen S. Thresholds for the cost–effectiveness of interventions: Alternative approaches. *Bulletin of the World Health Organization* 2015; 93:118–24. doi: [10.2471/BLT.14.138206](https://doi.org/10.2471/BLT.14.138206)
12. Woods B, Revill P, Sculpher M, and Claxton K. Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. *Value in Health* 2016; 19:929–35. doi: [10.1016/j.jval.2016.02.017](https://doi.org/10.1016/j.jval.2016.02.017). Available from: <http://dx.doi.org/10.1016/j.jval.2016.02.017>

E5 Glossary of epidemiologic and health economic terms

Box 1: Glossary (adapted from Antillon et. al 2022 [1] under a CC-BY 4.0 licence.)

EPIDEMIOLOGY TERMS

Intervention Interventions are separate activities to address a health need (e.g. active screening (AS) or vector control (VC)).

Strategy A strategy combines interventions with specific coverage. In this paper, we simulate strategies with and without an improvement in AS and with and without VC (e.g. Strategy 1 is passive screening (PS) and mean AS, and Strategy 6 is PS, intensified AS and full VC).

Elimination of transmission (EoT) Globally this is the 2030 goal for gHAT; here we also consider local EoT for health zones. The feasibility of EoT is expressed as a probability equal to the proportion of our simulations in which new infections are zero before a given year (usually 2030).

Objective The objective is the overarching goal of the decision maker; this could be EoT by 2030, minimising costs, or delivering a cost-effective programme compared to other diseases. We assume the objective is country-wide and different regions may need different strategies to meet the objective.

Disability-adjusted life-year (DALY) In order to present the burden of disease as one common metric across diseases, DALYs are calculated in cost-effectiveness analyses. This is the sum of the years lived with disability due to the disease and the years of life lost by fatal cases.

HEALTH ECONOMICS TERMS

Parameter uncertainty Uncertainty in the level of transmission or the costs of interventions due to unknown underlying parameters. See Text S4 for the explanation of our parameterisation of the health outcomes and cost model.

Willingness-to-pay (WTP) or cost-effectiveness threshold The amount of money that payers would pay to avert one DALY arising from the disease in the analysis (gHAT). No specific threshold is recommended, but a recent analysis shows that the WTP in DRC is between 5–230 USD per DALY averted [10–12].

Incremental cost-effectiveness ratio A ratio of marginal cost for a marginal benefit, calculated as follows:

$$ICER = \frac{\Delta \text{Costs}}{\Delta \text{DALYs}} = \frac{\text{Costs}_{\text{strategy}} - \text{Costs}_{\text{next best}}}{\text{Effects}_{\text{strategy}} - \text{Effects}_{\text{next best}}}$$

Cost-effective strategy The strategy where the ICER is less than the WTP (or cost-effectiveness threshold). We say that the cost-effective strategy is “conditional” on the WTP.

Dominated strategy A strategy that costs more than the minimum cost intervention while reducing the burden by a smaller degree. This strategy ought not to be implemented.

Weakly dominated strategy (or strategies under extended dominance) A strategy in which the ICER is higher than the next more expensive strategy. This strategy is less efficient than the next more expensive one and should not be implemented. For further illustration of weak dominance, see Supplementary Section, page 46 of Antillon et. al 2022 [1].

Net monetary benefit The net benefits (NMB) framework is derived from ICERs but also takes uncertainty into account.

$$NMB|WTP = WTP \times \Delta \text{DALYs} - \Delta \text{Costs}$$

The optimal strategy at a given WTP is the strategy with the highest mean NMB at that value of WTP.

Optimal strategy Analogous to the cost-effective strategy when no uncertainty is assumed, this is the strategy that is recommended by the NMB framework.

E6 Tables and Figures

Term	Description
Active screening (AS)	Mobile teams travelling to at-risk villages to test any person willing to participate
High risk	Individuals with the greatest risk of gHAT infection
Intensified (Int.) active screening (Int. AS)	Screening coverage (% people) at either the historic maximum or at 30% if the historic maximum is lower than this value
Intervention	Tools, treatments or approaches used to prevent or treat the infection
Low risk	Individuals with the lowest risk of gHAT infection
Mean active screening (Mean AS)	Screening coverage (% people) at the mean of the last five years for a region
Passive screening (PS)	Testing self-presenting individuals for gHAT at fixed health facilities
Reactive screening (RS)	Testing in specific locations in response to cases detected through passive screening
Treatment	Treatment of confirmed cases with either fexinidazole (oral drug course) if eligible, or pentamidine or NECT. Acoziborole (oral single-dose cure) may be used in the future if approved but is not considered in this analysis.
Vector control (VC)	Methods used to reduce or eradicate the vector, e.g. tsetse, that transmits infection
Targeted vector control (Targeted VC)	An adapted method based on that previously used by LSTM to identify areas with high case density at which to focus Tiny Target deployment efforts along waterways
Full vector control (Full VC)	Considers the deployment of Tiny Targets throughout all waterways in a health zone

Table E1: Terms used to describe the interventions and the strategies

Coordination	Total No. HZ	No. HZ	Included		Excluded - insufficient data			Excluded - urban locale		
			Cases 2000- 2020	Populatio (mil- lions)	No. HZ	Cases 2000- 2020	Populatio (mil- lions)	No. HZ	Cases 2000- 2020	Populatio (mil- lions)
Bandundu Nord	20	18	36369	3.6	2	6	0.2	0	0	0.0
Bandundu Sud	32	19	30456	4.8	12	27	2.4	1	64	0.3
Equateur Nord	39	22	19340	4.7	17	21	3.6	0	0	0.0
Equateur Sud	30	9	1622	1.3	21	55	4.0	0	0	0.0
Isangi - Bas-Uélé	6	2	3297	0.2	4	3272	0.5	0	0	0.0
Isangi - Tschopo	29	4	2792	0.7	25	55	3.9	0	0	0.0
Kasai Occidental	45	18	6314	4.4	26	66	6.5	1	172	0.3
Kasai Oriental	35	22	17415	6.4	5	31	1.0	8	2874	3.1
Kinshasa	36	13	3027	4.2	9	108	1.8	14	1107	5.0
Kongo Central	30	17	4673	2.6	13	40	1.9	0	0	0.0
Maniema Katanga	29	13	4583	3.3	16	30	3.3	0	0	0.0
Sankuru	16	8	2053	1.3	8	17	1.1	0	0	0.0
No Coordination	172	NA	0	0.0	172	58	39.7	0	0	0.0
Total	519	165	131941	37.6	330	3786	69.9	24	4217	8.7

Table E2: Summary of demographics characteristics and HAT case burden of health zones that were included compared to those excluded from the analysis. The health zones were omitted if there were fewer than 10 data points: in other words the years of AS reports available plus the years of PS reports available equalled less than 10, or if we did not believe that transmission could take place in the health zone because it was urban. Fewer than 3% of cases occurred in health zones with insufficient data and another 3% occurred in health zones that we have excluded because of their urban locale, where we believe there is no transmission. Abbreviations: HZ: health zones (zone de santé in the original French). AS: active screening, PS: passive screening.

Coordination	No. HZ	Pop. per HZ (thousands)	Pop. subtotal (millions)	2000-2020		2016-2020	
				Cases per HZ ^a	Sum cases	Cases per HZ ^a	Sum cases
Bandundu Nord	18	180 [110–367]	3.60	1748 [37–7186]	36369	66 [3–210]	1278
Bandundu Sud	19	249 [154–358]	4.80	592 [10–6827]	30456	36 [1–183]	1194
Equateur Nord	22	188 [84–427]	4.70	474 [25–4298]	19340	2 [0–29]	113
Equateur Sud	9	171 [45–212]	1.30	92 [19–550]	1622	2 [0–15]	34
Isangi - Bas-Uélé ^b	2	110 [88–133]	0.20	1648 [1390–1907]	3297	0 [0–0]	0
Isangi - Tshopo ^b	4	198 [106–208]	0.70	579 [41–1593]	2792	23 [0–55]	101
Kasai Occidental	18	230 [117–420]	4.40	180 [9–1982]	6314	12 [0–85]	446
Kasai Oriental	22	265 [153–543]	6.40	472 [56–4567]	17415	8 [1–58]	307
Kinshasa	13	338 [90–594]	4.20	98 [35–858]	3027	5 [0–43]	143
Kongo Central	17	133 [83–251]	2.60	249 [15–912]	4673	4 [0–51]	169
Maniema Katanga	13	237 [107–417]	3.30	391 [31–691]	4583	14 [0–74]	309
Sankuru	8	150 [95–239]	1.30	218 [13–773]	2053	20 [1–104]	331
Total	165	210 [45–594]	37.58	342 [9–7186]	131941	9 [0–210]	4425

^a Cases are shown per health zone: median [minimum-maximum].

^b Isangi coordination has been separated into two subregions in this analysis. Bas-Uélé is constituted of Ango health zone in Bas-Uélé Province and Doruma health zone in Haut-Uélé Province. Tshopo is constituted of Isangi, Yabaondo, Yahisuli, and Yakusu health zones in Tshopo province.

Table E3: Summary of the demographic characteristics and recent vs complete case burden in health zones in the analysis, stratified by the coordinations delineated by the programme national de lutte contre la Trypanosomiasse humaine africaine (PNLTHA-RDC). Abbreviation: HZ: health zone (zone de santé in the original French).




Figure E1: Warwick gHAT intervention model compartmental diagram. Purple boxes denote human infection/risk compartments, red boxes denote tsetse infection compartments, and green boxes denote non-human animal infection compartments (only in the model variant with possible animal transmission). Solid lines represent the transition between infection states, and dashed lines are transmission pathways. Reproduced from [8] under a CC-BY licence.




Figure E2: a) Process of analysis. b) Future strategies simulated in most health zones. *Mean AS* is equal to the mean coverage of AS between 2016–2020, *Int. AS* is 30% or the historical maximum coverage between 2000–2020, whichever is higher. c) Future strategies simulated in Ango, Ganga, and Doruma health zones of the Bas Uélé region. We do not simulate mean AS from 2016–2020 in these health zones as there was no AS during this period, hence *Restart PS* is effectively equivalent to this strategy. In these health zones, we take *Int. AS* to be the mean of 2010–2014 when MSF was operating in the region. In all health zones, the *Targeted VC* strategy only simulates VC along rivers in regions with high case density, and because the cases may be diffuse in some health zones, this strategy is not present in some health zones. Whereas the *Full VC* strategy involves the deployment of Tiny Targets throughout all large rivers in a health zone, regardless of the density of the cases. *Intervention cessation:* All strategies assume that AS will cease after 3 years of AS with zero cases in either AS or PS, followed by another AS in year 5 with no cases. RS is triggered if a case is found in PS and stops using the same 3+1 algorithm. VC stops after 3 years of no cases. PS is stopped 5 years after AS and RS have ceased. See the glossary and Table ?? for details of abbreviations. AS: active screening, PS: passive screening, VC: vector control, EoT: elimination of transmission.




Figure E3: Treatment model. Treatment for diagnosed gHAT patients is modelled as a branching tree process of possible health outcomes, including eligibility for novel fexinidazole. Abbreviations: SAE: Serious adverse events, IP: inpatient care, OP: outpatient care.




Figure E4: Optimal strategies in each health zone of DRC compared to the status quo strategy (first column) depending on the level of investment (denominated by USD per DALYs averted), or by different target dates to maximize the probability of EoT. Colours represent the optimal strategy, and numbers represent the probability of achieving EoT with that colour strategy by 2030. Strategies that do not reach a 90% probability of achieving EoT by 2030 are marked with an 'x'. AS: active screening, PS: passive screening, VC: vector control, DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E5: Maps and bar charts of optimal strategies according to economic or elimination goals for the whole of the DRC (time horizon 2026–2040 and 3% discounting, based on models estimated to 2000–2020 data). Maps show the optimal strategies depending on the status quo, minimum cost, and a WTP of \$250 and \$500, respectively. The final map shows the most efficient strategy with the maximum probability of EoT by 2030 and 2040 in each health zone of the DRC. Striped health zones are those where the probability of EoT by 2030 is less than 90%. Shapefiles used to produce this map were provided by Nicole Hoff and Cyrus Sinai under a CC-BY licence (current versions can be found at <https://data.humdata.org/dataset/drc-health-data>). The table denotes the expected number of health zones that will meet the EoT goal by either 2030 or 2040 under the different objectives. An interactive map can be found at <https://hatmepp.warwick.ac.uk/DRCCEA/v8/>. AS: active screening, PS: passive screening, VC: vector control, DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E6: Projected total cases reported, deaths, DALYs and economic costs in all the DRC with optimal strategies at different investment levels over time and for the period of 2026–2040. Values here show numbers of projected cases, deaths, DALYs and costs (undiscounted) over the time horizon 2026–2040 based on fits to 2000–2020 data. DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E7: Histogram of optimal strategies by coordination. Abbreviations: AS: active screening, PS: passive screening, VC: vector control, DALY: disability-adjusted life-year, EoT: elimination of transmission.




Figure E8: Total cases 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E9: Cases by the year 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E10: Total deaths 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E11: Deaths by the year 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E12: Total DALYs 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E13: DALYs by the year 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E14: Total costs 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E15: Total costs 2026–2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.

E6.1 Resource forecasts




Figure E16: Costs allocated to different activities, at different levels of investment, for the period 2027–2040. Abbreviations: AS: active screening, PS: passive screening, VC: vector control, S1: Stage 1 disease, S2: Stage 2 disease, S2L2: Stage 2 rescue medicine, DALY: disability-adjusted life-year, EoT: elimination of transmission.




Figure E17: Costs allocated to different activities, at different levels of investment by coordination, for the period 2026–2040. Abbreviations: AS: active screening, PS: passive screening, VC: vector control, S1: Stage 1 disease, S2: Stage 2 disease, S2L2: Stage 2 rescue medicine, DALY: disability-adjusted life-year, EoT: elimination of transmission.




Figure E18: Drugs used by the year 2026-2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.




Figure E19: Tests used by the year 2026-2040 at different levels of investment. Abbreviations: DALY: disability-adjusted life-year, WTP: willingness-to-pay (denominated in USD per DALY averted), EoT: elimination of transmission.